Still, the few head-to-head clinical trials that have been conducted show that Bexxar and Zevalin are as effective as Rituxan, if not better. In a study published in The Journal of Clinical Oncology in 2002, the tumors in 80 percent of patients who received chemotherapy and Zevalin shrank, compared with 56 percent who received chemotherapy and Rituxan. Of patients who received Zevalin, 30 percent went into complete remission, compared with 16 percent who got Rituxan.
If these numbers from the NY Times article is accurate than the onclogist you spoke with is wrong about Rituxan being better. Unless the trial mentioned in the article was a trial in follicular cell lymphoma.
